Mobile-health Network Solutions MNDR PHARMA
Company Overview
Mobile-health Network Solutions, an investment holding company, provides telehealth solutions primarily in Singapore. The company operates in two segments: Telemedicine and Other Services and Sale of Medicine and Medical Devices. It offers MaNaDr platform, a 360-degree healthcare ecosystem, which connects users and service providers through the range of healthcare services and product offerings that can be accessed through the mobile application and website, as well as Internet search engines. The company also provides a suite of medical-related and other services, including teleconsultations and health check-up services, vaccinations, skin and aesthetics services, and other services. In addition, it offers healthcare and wellness products through its online e-commerce platform; wholesale distribution of pharmaceutical products to clinics through MaNaPharma platform; and MaNaCare, a platform that provides a range of corporate healthcare and wellness services, including GP, specialist and allied healthcare panel services, tele-consultation services, in-person clinics, on-site health screening, and online marketplace, as well as wellness programs to corporate customers. Further, the company develops IT systems on mobile phone and web portals; operates pharmacies, clinics, and drug stores; and offers beauty and other personal care services, as well as other general medical services. Additionally, it offers health supplements, skincare, nutrition products and medical devices wellness, personal care; health screening packages; and online services such as medical screenings and procedures, such as serology and swab tests. The company was founded in 2009 and is headquartered in Singapore.
Why Investors Should Care
Revenue has grown at a 41.4% CAGR over the past five years.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -7.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 41.4%, profit CAGR -8466.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 41.37% |
| 1 Year: | -7.70% |
Compounded Profit Growth
| 5 Years: | -8,466.02% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -96.08% |
| 6 Months: | -72.66% |
| 3 Months: | -65.82% |
| 1 Month: | -17.51% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)33.27 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 41.4% over 5 years.
CONS
- Earnings shrank at -8466.0% CAGR over 5 years.
- Trading 96.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MNDR Mobile-health Network Solutions PHARMA | 1.46 | -0.10 | $1.30M | 0.00% | - | -47.59% | 41.37% | -8,466.02% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 6.99M | 7.87M | 13.97M | - |
| Cost of Revenue | 5.05M | 6.78M | 11.43M | - |
| Gross Profit | 1.94M | 1.09M | 2.54M | - |
| Operating Expenses | 1.74M | 4.36M | 18.24M | - |
| Operating Income | 196.02K | -3.26M | -15.70M | - |
| EBITDA | 283.11K | -3.17M | -15.55M | - |
| Interest Expense | 0 | - | - | - |
| Pretax Income | 258.47K | -3.21M | -15.62M | - |
| Tax Provision | 165.78K | 0 | -19.19K | - |
| Net Income | 92.70K | -3.21M | -15.60M | - |
| Diluted EPS | 0.11 | -3.78 | -18.09 | -3.82 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Total Assets | 10.76M | 3.44M | 7.95M | - |
| Current Assets | 10.54M | 2.72M | 7.29M | - |
| Cash & Equivalents | 10.24M | 2.23M | 6.71M | - |
| Inventory | 71.66K | 146.38K | 163.99K | - |
| Receivables | 112.53K | 74.31K | 111.07K | - |
| Total Liabilities | 2.32M | 3.81M | 3.81M | - |
| Current Liabilities | 1.27M | 2.50M | 3.16M | - |
| Long Term Debt | - | - | - | - |
| Total Debt | 59.12K | 395.78K | 376.01K | - |
| Total Equity | 8.44M | -367.20K | 4.14M | - |
| Shares Outstanding | 850.00K | 850.00K | 862.29K | 1.04M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 |
|---|---|---|---|
| Operating Cash Flow | 975.66K | -2.25M | -6.41M |
| Investing Cash Flow | -15.21K | -186.00K | -134.21K |
| Financing Cash Flow | 9.23M | -5.80M | 10.88M |
| Capital Expenditure | -15.21K | -186.00K | -134.21K |
| Free Cash Flow | 960.45K | -2.43M | -6.54M |
| Net Change in Cash | 10.19M | -8.24M | 4.34M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Gross Margin % | 27.7% | 13.9% | 18.2% | - |
| Operating Margin % | 2.8% | -41.4% | -112.4% | - |
| Net Margin % | 1.3% | -40.8% | -111.7% | - |
| ROE % | 1.1% | 875.1% | -376.9% | - |
| ROCE % | 2.1% | -346.0% | -327.7% | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HRT Financial LP | 1.88% | 16.71K | $21.38K |
| 2 | Citadel Advisors Llc | 1.19% | 10.61K | $13.58K |
| 3 | UBS Group AG | 0.89% | 7.91K | $10.12K |
| 4 | SBI Securities Co., Ltd. | - | 15 | $19 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MNDR
Mobile-health Network Solutions Announces Effective Date of Reverse Stock Split - TMX Newsfile
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNRi1vcVhfN0RGYi1nT3c5dzZnemtnMmlWMkMtbGJqa2JxNEdGei1peUhRSzZsNGRHWHQxbHFsbmdBZjZtLVc1MFpJTWRuZEMzamRQSjNaNXNEYUFTLTlPLUxJZ05RaTJ6MXk0Q01sOW15cl9HeU0xZzVVb2RfeGNMV0Y2bkJCVFBFX1pwVW…
MNDR - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9PZFhhVHhNTGRuOGNFbnlFSDUyT0FxRTF4dHdqaUIwNU9wTEtrOXBmLU82N2hYckFmTjlyb053TDBXUUNYQUE?oc=5" target="_blank">MNDR</a> <font color="#6f6f6f">Finviz</font>…
Mobile-health Network Solutions Revenue Breakdown – NASDAQ:MNDR - tradingview.com
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE44T1FJZFZabEVMdzMyUlJOZTZqOXZRaUhvaTBUTUplTVphWDlmQVBQTjJaSnNQTEkyWTN1TEJOSXNTN3lUZlEwMjYxakFmTlg4OXJESkxWYjFCYlQ5QTk2eVJpMmlQVms2SHR2bEo0dWF0RTVOUm5j?oc=5" target="_blank">Mobile-…
Mobile-health Network Solutions Sees Stock Surge: Strategic Moves Spark Optimism - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPUXdWUFpkMU1vOS1OWi1Dbkg3UVZzQ2dQRk52eGprWTZiSGZ4ZWVERktKNWNWWlZ4cXk5QmxYdmtEYUpBVUNzMHlxSGw2bHUxZXByOEduZloyOTdHWWhXTXBoYWNDNmxVZUNTM09uMndKcGd4VXJxT1c5OWtoX20zZ0xENktUcURtODFhWQ…
Mobile-health Network Solutions signs MOU for $119m investment By Investing.com - Investing.com
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPQ2xrbG03WkZLdTFUTzBjTWFGMzJIQnRUYTJUX1BlWXlFNGpKUl9zTVhfQnVGVUUydHJvaGtOdlBwMVNKY0hIQ3BMOTlTNnBsQmVVNDBvRUM1UVMtUWtGV1Y1WTgtN1RxbkdFUmdudTE2b2ljTENHNmZUUWxEVG1seXlvNFluS3ZSdVBSM2…
MNDR Stock Jumps Amid Strategic Expansion Plans - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNMWhwbFhfcGhlR0djeThySzRfcVZncUt3ZE56V2pVbE9ZODR4YjE2aDl4RGFBQjdBWnZMaHlkbWp5YVBwMGhpMVItVVJWR1pTdTE1RlJwWjFVaTNhX2FpXy0ybzBVR3liRUVpdzBZWGx1REdrNzhQQW8tS2IzSnZWLVZzSG5OUnI1NzBz?o…
MNDR — Frequently Asked Questions
What is the current share price of Mobile-health Network Solutions (MNDR)?
As of 2026-09-19 21:16 PDT, Mobile-health Network Solutions (MNDR) trades at $1.46 on NasdaqCM. Its 52-week range is $1.42 to $37.20.
What is the market capitalisation of MNDR?
Mobile-health Network Solutions (MNDR) has a market capitalisation of $1.30M on NasdaqCM.
What is the P/E ratio of MNDR?
MNDR trades at a trailing price-to-earnings (P/E) ratio of -0.10. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.09.
What is the return on equity (ROE) of MNDR?
MNDR has a return on equity (ROE) of -47.59%.
Is MNDR a good stock to buy?
This page provides a data-driven analysis of Mobile-health Network Solutions (MNDR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.